We offer daily assistance for technical and scientific matters.
Central Nervous System Inflammatory Disease
Inflammatory disease of the central nervous system comprises a large spectrum of autoimmune diseases. Multiple sclerosis is the most common chronic human inflammatory demyelinating disease of the central nervous system and causes of disability in young adults.
What is Multiple Sclerosis?
Multiple Sclerosis is characterized by the disseminated demyelination of nerve fibers of the brain and spinal cord and may lead to physical disability, cognitive impairment and decreased quality of life.
Usually, Multiple Sclerosis can progress with individual relapses (attacks or exacerbations) or more gradually.
Presence of intrathecal IgG suggests inflammatory disease of the Central Nervous System (CNS), such as caused by multiple sclerosis (MS).
Oligoclonal bands detection in CSF : the gold standard assay to objectively detect CNS local IgG synthesis.
20-40
years is the most common age of onset for Multiple Sclerosis
2.9
million people are affected by Multiple Sclerosis worldwide
3.2
months is the median time to diagnosis using the 2017 McDonald criteria
Knowledge & Science
We aim to educate and share scientific and medical educational information with our customers all around the world.
Understand in 2 minutes how capillary electrophoresis works, and why it gives such high and clear resolution in lab testing.
Instrument for diagnosing Central Nervous System Inflammatory Disease
The compact and affordable automation of Capillary Electrophoresis.
Evolution makes the difference.
A concentrate of Sebia’s expertise in a high throughput instrument.
Capillary Electrophoresis solution to meet your high capacity needs.
The high throughput solution for newborn hemoglobin disorders screening.
Large menu with high quality results on gel electrophoresis.
Efficiency re-dIFined.
Authentically clear!
Small Footprint - Big Impact.
a) Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, Patti F, Pozzilli C, Preziosa P, Trojano M. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022 Oct;269(10):5382-5394. doi: 10.1007/s00415-022-11193-w. Epub 2022 May 24. Erratum in: J Neurol. 2022 Dec;269(12):6690-6691. doi: 10.1007/s00415-022-11385-4. PMID: 35608658; PMCID: PMC9489547.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.